Q1 2024 KORU Medical Systems Inc Earnings Call Transcript
Key Points
- Record-setting quarterly revenue of $8.2 million, marking an 11% increase compared to the previous year.
- Achieved a gross margin of 62.3%, maintaining a margin above 60% for the third consecutive quarter.
- Significant reduction in cash burn to $700,000 from $5.2 million in the same period last year, demonstrating improved financial management.
- Strong international growth with a 63% increase in revenue, driven by successful market expansions and new distributor onboarding.
- Progress in novel therapies with three new collaborations signed in 2024, including a promising oncology collaboration.
- Domestic core growth was modest at 4%, indicating potential challenges in more saturated markets.
- Novel therapies revenue declined by 21% compared to Q1 2023, reflecting the variable and milestone-based nature of this revenue stream.
- Guidance for the year was only reaffirmed, not increased, despite a strong first quarter, suggesting caution about future performance.
- Some regulatory delays in international markets like Japan, which could affect the timing of expected revenue contributions.
- Ongoing need to manage inflationary pressures and production line startup costs, which could impact gross margins in the future.
Greetings, and welcome to the Corus Medical Systems first quarter 2024 financial results conference call and webcast. (Operator Instructions)
As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Lisa of the Gilmartin Group. Please go ahead, Melissa.
Thank you, Rachel, and good afternoon, everyone. Earlier today, KORU Medical Systems released financial results for the first quarter ended March 31, 2020. For a copy of the press release is available on the company's website.
During this call, we will make certain forward-looking statements regarding our business plans and other matters. These comments are based on our predictions and expectations as of today, actual events or results could differ materially due to many risks and uncertainties, including those mentioned in the associated press release and our most recent filings with the SEC.
We assume no obligation to update any forward-looking statements. I encourage listeners to have our press
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
